



#NAVARRATRANSFRONTERIZA #NAVARREINEUROPE

CROSS-BORDER AND EUROPEAN NAVARRE'S PARTICIPATION IN BIOHEALTH

CROSS-BORDER AND EUROPEAN NAVARRRE'S PARTICIPATION IN BIOHEALTH

This guide is published on the occasion of the 8th New Aquitaine - Euskadi - Navarre Bio-Health Meetings, held on October 16 and 17, 2023 in Pamplona-Iruña. Its objective is to gather the different cross-border and European projects in which Navarre has participated or participates through different public and private agents. It also offers different financing tools for biohealth projects in cross-border and European cooperation.

Edition

**Memory and Coexistence, External Action
and Basque Department**

General Directorate of Foreign Action

C/ Yanguas y Miranda 27

+34 848 426 091

accionexterior@navarra.es

accionexterior.navarra.es

Collaborator



NAVARRE



NAVARRRE AND THE BIOHEALTH INDUSTRY

STRATEGIC LOCATION

The Foral Community of Navarre is located in the north of Spain, at the western end of the Pyrenees, where it shares a 163-kilometre stretch of border with France. It has a territorial extension of 10,391.08 square kilometres.

Navarre is a European crossroads between the Mediterranean and the Atlantic, and connects Spain with the rest of Europe. Its capital, Pamplona, is located at a comfortable distance from several international airports (Bilbao, Zaragoza, Biarritz and Bordeaux). And it has daily high-speed rail connections with Madrid and Barcelona.

Multimodal facilities are being planned and also to form part of the Lisbon-Paris European Axis.

IN FIGURES

0,97

QUALITY OF LIFE

With an OECD development index (IDH) of 0.97, Navarre is one of the regions with the highest standard of living in the world and the region with the highest quality of life in Spain according to the National Institute of Statistics (INE, 2021).

3rd


R+D+I

Navarre is a Strong Innovator region according to the RIS 2023. Navarre is the third Spanish region that invests the most per inhabitant in R+D+i with an investment of 1.91% compared to the regional GDP. In addition, it is one of the European regions that has its own tax system.

26%

CONTRIBUTION OF THE INDUSTRIAL SECTOR TO GDP

Navarre's industrial fabric plays a very important role in its economy, representing more than 26.1% of GDP, almost 13 points above the Spanish and EU average.



A PIONEER INDUSTRY

1.16

Biotechnology business intensity in Navarre is the highest in Spain, with 1.16 biotech companies per 1,000.

S4

Navarre is a pioneer region in the approval of a comprehensive strategy for personalized medicine and Biohealth is included in its Smart Specialization and Sustainable Strategy (S4).

83

The health industry sector in Navarre has 83 companies and a turnover of around 800 million euros. The biotechnology sector employs more than 2,400 professionals in Navarre.

1^o

The International Consortium for Personalized Medicine (ICPer-Med) has recognized the "PharmaNAGEN" project from Navarre as the "Best International Practice in Advanced Medicine".

44.3


€44.3 million were invested in research in the biotechnology sector in 2020.

2

With 2 universities; University of Navarra (UNAV); top 250 range in the world in Clinical and Health and Public University of Navarra (UPNA); best university of Spain in Regional Engagement, Navarre is in the top 10 of European regions with the highest share of people aged 25-34 with tertiary education.

PROJECTS

ONCONAEN



European programme

Eurorégion Aquitaine-
Euskadi-Navarre

Summary

The ONCONAEN project brings together public and private actors from the 3 regions around chronic diseases and aging: identification of vulnerable people by completing detection tools thanks to vulnerability biomarkers, optimization of follow-up during treatment by developing telemonitoring tools, organization of post-cancer surveillance, with telemonitoring and teleconsultation tools.

Navarre participation

SODENA
DESARROLLO DE NAVARRA
NAFARROAKO GARAPENA




Hospital
Universitario
de Navarra

Nafarroako
Ospitale
Unibertsitarioa

French partners

GIPSO, Cluster TIC Santé Nouvelle Aquitaine
and CCI Bayonne Pays Basque

VIVIfy



European programme

EPLUS

Summary

VIVIfy was created to support European healthcare systems in meeting the challenges of efficient care delivery and system reorganization, and to meet the future needs of an aging and frail society by finding ways to improve quality of life, highlighting the positive effects of sport and exercise programs.

Navarre participation

upna

Universidad Pública de Navarra
Nafarroako Unibertsitate Publikoa

French partner

Centre Hospitalier Universitaire (CHU)
de Toulouse

VIVIfrail

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme
ERASMUS+

Summary

The VIVIfrail project aimed to enhance the promotion and prescription of a multicomponent physical exercise program, involving professionals from different fields, such as physicians, nurses, practitioners, trainers, sports technicians and managers, home care assistants or nursing home staff. These professionals worked on the promotion of physical exercise, and received updated training on tools and techniques to identify frailty and risk factors for falls, helping frail elderly patients to implement strategies for healthy aging, based on multicomponent exercise programs.

Navarre participation



French partner

Centre Hospitalier Universitaire (CHU)
de Toulouse

TARGEPI LIVER

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme
H2020 - MSCA


Summary

Liver fibrosis represents a common pathogenic pathway in most chronic liver diseases (CLD) and cirrhosis, its final stage, represents a huge health burden. The aim of the project is the analysis of the expression, activity and pathological significance of DNA and histone methyltransferases in models of CHD and hepatocarcinogenesis; and secondly, the development of new effective specific inhibitors of DNA and histone methyltransferases with a good safety profile, which is essential when treating patients with compromised liver function. These new epigenetic therapies could be used to prevent progression of CLD and treat HCC, alone or in combination with existing drugs.

Navarre participation



I-MOVE-plus



European programme

H2020

Summary

Integrated monitoring of vaccine effects in Europe: a platform to measure and compare the efficacy and impact of influenza and pneumococcal vaccines and vaccination strategies in the elderly.


Navarre participation



French partners

Assistance Publique Hôpitaux de Paris, Centre Hospitalier Universitaire, Santé Publique France, Réseau Sentinelles, Université de Corse Pascal Paoli-France and EpiConcept

MED-HEALTH



European programme

ERASMUS+

Summary

Mediterranean Alliance for Health. Project aimed at training public health managers in Arab countries.

Navarre participation



LASALUS

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme ERASMUS+

Summary

The LASALUS project aims to increase and improve, in Latin America, the access of professionals from outpatient centers, hospitals and health centers to Higher Education in Healthcare Management, through the development and implementation of an international cluster curriculum in healthcare management characterized by distance learning and computer simulation training. Health Management characterized by the distance learning modality and computer simulation training. Distance learning will provide greater geographical accessibility and flexibility of time and pace.

Navarre participation



French partner

École des Hautes Études en Santé Publique (EHESP)

PROCROP

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme H2020

Summary

PROCROP's goal is to develop in three pilot clinical trials a suitable individualized vaccine technology for castration-resistant prostate cancer and metastatic ovarian cancer that complements currently available therapies to increase their efficacy.

Navarre participation



ehcoBUTLER



European programme
H2020

Summary

A global ecosystem for independent and healthy living for older people with mild cognitive impairment.


Navarre participation

Asesoría de Barreras
Arquitectónicas ASBAR S.L.

French partners

E-Seniors and Initiation des Seniors
aux NTIC Association

MY FISH CURE



European programme
H2020


Summary

The MY FISH CURE project seeks to overcome the major barriers that currently prevent the use of zebrafish avatars as in vivo models for patient-directed interventions, so that they can be used in a clinical context rather than in a research or drug development context.

Navarre participation



REFBIO 2



European programme POCTEFA

Summary

The overall objective of REFBIO II is the consolidation of cross-border cooperation in the field of biomedicine, through the intensification of collaboration between research entities, the stimulation of innovation and the transfer and exploitation of R&D results to companies and clusters of the territory. REFBIO II is a continuity project that incorporates new partners, a new territory and original elements of REFBIO I and allows to promote innovation and the effective transfer of biomedical R&D results and promote its valorization in the Pyrenees area.


Navarre participation



French partners

Clúster Osasuna Santé, Université Toulouse III Paul Sabatier and Centre Hospitalier Universitaire de Toulouse

ONCONET



European programme SUDOE

Summary

European network for transnational research and innovation in oncology.


French partners

Université Toulouse III, Toulouse Tech Transfer, L'Institut universitaire de Toulouse Oncopole, Canceropole. Grand Sud-Ouest, Cancer-Bio-Santé (CBS) and Inserm

Navarre participation



BERTAN



European programme

POCTEFA

Summary

Design and implementation of innovative solutions for active and healthy aging in rural districts of the cross-border area, thus improving access to services.

Navarre participation



IRURTZUN ESKUALDEKO
GIZARTE ZERBITZUETAKO MANKOMUNITATEA
MANCOMUNIDAD DE SERVICIOS SOCIALES
DE LA ZONA DE IRURTZUN

French partner

Centre Intercommunal d'Action Sociale
Pays Basque



MYELOMANEXT



European programme

H2020

Navarre participation



Universidad
de Navarra

Summary

Multiple myeloma (MM) represents a unique model for investigating cancer stem cells (CSCs), circulating tumor cells (CTCs), and mechanisms of malignant transformation and chemoresistance. Despite substantial improvement in the outcome of MM patients, the vast majority of patients eventually relapse and the disease remains largely incurable. For those patients who fail to achieve deep remissions, biologically targeted research on the ultra-chemoresistant minimal residual disease (MRD) clone may allow us to understand the cellular mechanisms driving chemoresistance and design new therapies to overcome it; importantly, this effort should be equally pursued in two other key players: CSCs and CTCs. On the other hand, it is undeniable that a selected group of patients experience long-term survival regardless of the depth of response achieved, but we fail to understand the mechanisms underlying continued disease control. Is it due to persistent residual benign clones? Is it due to immune surveillance? Here, we will integrate next-generation flow cytometry and sequencing to define i) the signature of ultrachemo-

resistant CTCs and MRD cells, ii) the hierarchical place of putative CSCs, iii) the genomic landscape of benign vs. malignant clones; and iv) the role of immune surveillance in achieving functional cures. Therefore, we will characterize for the first time the highly professional subclones responsible for malignant transformation, disease dissemination and dramatic relapses after optimal response to therapy. Importantly, the innovative approach of this scientific proposal relies heavily on the use and expertise of highly sensitive next-generation flow cytometry, coupled with DNA and RNA sequencing optimized for low cell numbers, and longitudinally available prospective patient samples in the context of well-controlled clinical trials. In this regard, we believe that all requirements are met to carry out this innovative research program.

NOA

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Navarre participation



Summary

The basis of the NOA device is its ability to measure the Exhaled Nitric Oxide Fraction (FeNO) of human breath, which is a marker indicating the existence and extent of upper airway inflammation caused by asthma. The NOA is the only portable device capable

of monitoring asthma with high accuracy, and is easy to use and very fast (5 seconds) thanks to an innovative patent-protected technological development that combines electronics and pneumatics, sensors and mathematical algorithms.

AT HOME

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

ERASMUS+

Navarre participation



Summary

To develop, through new technologies, the acquisition of basic skills in home help.

French partners

IRFSS Aquitaine and Association de Maintien et de Soins à Domicile de la Haute Gironde

ARSIM2CARE

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

ERASMUS+

Navarre participation



Summary

The main objective of this project is the development of an AR software that combined with the anatomical models, helps the student acquire technical skills in the performance of invasive clinical procedures, through the visualization of internal anatomical structures.

ZEBRAONCOFISH

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme
H2020

Summary

ZEBRAONCOFISH proposes the use of zebrafish avatars as an in vivo platform to guide therapeutic decisions in actionable interventions targeting the cancer patient.

Navarre participation



EN_ACTI2NG

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme
H2020 - MSCA

Summary


The EN-ACTI2NG program aims to:

- 1) Train PhD students with expertise in the development of new and improved T cell-mediated cancer immunotherapies.
- 2) Equip PhD students with the ability to establish effective communication between academic and industrial research environments and between scientists and the general public.
- 3) Improve T cell-mediated cancer immunotherapy by identifying and developing novel cancer-specific immune receptors and improving their function by identifying and modifying their molecular mechanism of action.

Navarre participation



INTEGRATE



European programme

3rd Health Programme

Summary

The “Joint action on integrating HIV, viral hepatitis, tuberculosis and STI prevention, testing and linkage to care strategies in Europe” (INTEGRATE) has the overall objective of increasing integrated early diagnosis and linkage to prevention and care of HIV, viral hepatitis, tuberculosis and STIs in EU Member States by 2020.

Navarre participation



EU-JAMRAI



European programme

3rd Health Programme

Summary

Ensure that microbial resistance and health-care associated infection control policies are adopted and implemented in all EU Member States in a coordinated manner, ensuring that national specificities are taken into account, in line with ECDC and WHO guidelines and recommendations, and in conjunction with other European initiatives.

Navarre participation



French partner

Institut National de la Santé et de la Recherche Médicale and Ministère des Affaires Sociales et de la Santé

RESPINE

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Summary

To develop the first effective and rigorously tested treatment for DDD, RESPINE intends to evaluate, through a phase 2b, multicenter, randomized, controlled clinical trial involving 112 DDD patients, the efficacy of an allogeneic therapy based on intervertebral mesenchymal stem cells (MSCs). This innovative therapy aims to reduce pain and disability quickly (within 3 months) and durably (at least 24 months). In addition, the consortium aims to provide new insights into the immune response and safety associated with allogeneic intradiscal injection of BM-MSCs.

Navarre participation



Universidad
de Navarra

French partners

Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale, Université Toulouse III Paul Sabatier, Assistance Publique Hôpitaux De Paris, Université de Montpellier, ECRIN European Clinical Research Infrastructure Network, Centre Hospitalier Universitaire Montpellier, Centre Hospitalier Universitaire de Nantes, Centre Hospitalier Universitaire de Rennes and Human Cell Design

WASHER-CAP

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Summary

ABANZA TECNOMED has developed and patented WasherCap as a response to the problems detected in the field of knee ACL reconstruction devices. It is a novel connective tissue fixation device specifically designed for cruciate ligament reconstruction using soft material fascicles.

Navarre participation



EMERGENCIAS MÉDICAS – EMS

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

B-solutions

Summary

Cross-border agreements to avoid administrative barriers in cross-border emergency health intervention.

Navarre participation



CARDIOREG

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

Eurorregión Nueva
Aquitania, Euskadi,
Navarra

Summary

Promoting cooperation towards innovation in the treatment of cardiovascular diseases: new regenerative therapies for myocardial infarction.


Navarre participation



French partner

Université de Bordeaux

CINK



European programme

H2020 - MSCA

Navarre participation




Cima
Universidad
de Navarra

Summary

Adoptive transfer (AT) of expanded NK cells by this novel method will result in improved anti-tumor responses following mAb therapy, even in tumor cells expressing a limited amount of the target molecule, thereby limiting cancer relapse rates. Furthermore, due to the overall improvement in NCF, the combination of NK

AT cells with hematopoietic stem cell transplantation (HSCT) is also expected to increase antitumor responses; the efficacy of which to date has proven to be rather limited.

ANETO



European programme

POCTEFA

Summary

Prevention of childhood obesity. The project integrates nutritional aspects through a prevention program for school and canteens with physical activity adapted to children.

Navarre participation

Gobierno
de Navarra



Nafarroako
Gobernua




Instituto Navarro del Deporte
Nafarroako Kirolaren Institutua



French partners

Réseau Sport 64, Union Sportive de l'Enseignement du Premier Degré (USEP 64), Direction Départementale de l'Éducation Nationale des Pyrénées-Atlantiques (DSDEN 64), Réseau Canopé and Les PEP64

ICTUSnet



European programme
SUDOE

Summary

ICTUSnet is based on new data analysis technologies and a network to ensure the dissemination of information and best practices on stroke and improve clinical decisions.


Navarre participation



French partners

Centre Hospitalier Universitaire de Montpellier and Centre Hospitalier Universitaire de Toulouse

IMLINFO



European programme
POCTEFA

Summary

IMLINFO is a cross-border network of personalized immunotherapies for non-Hodgkin's lymphoma (NHL) that brings together 7 organizations from Spain and France. Its main objective is to determine the efficacy of new immunotherapy treatments by creating a repository of NHL tumors associated with a 3D culture platform.

Navarre participation



French partner

Institut National de la Santé et de la Recherche Médicale

GHELP

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

SUDOE

Summary

The GHELP project aims to improve current health programs for the early detection of hearing loss through the development and validation of an innovative and cost-effective genetic diagnostic tool: the GHELP panel, composed of the most relevant genes related to hearing loss. Using NGS (Next Generation Sequencing) technology, we will be able to analyze at the same time, with a single blood sample, certain genes. This will allow us to better understand the genetic origin of this disease.

Navarre participation



Universidad
de Navarra



Clínica
Universidad
de Navarra

Instituto de Salud
Pública y Laboral
de Navarra



Nafarroako Osasun
Publikoaren eta Lan
Osasunaren Institutua

French partner

Centre Hospitalier Universitaire de Montpellier

Tumor-Treg-Targeting

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020 - MSCA

Summary

The project will employ the latest advances in antibodies design to target the next generation of biologics directly to tumor Treg cells or to the tumor microenvironment itself. In this way, we will be able to specifically modify the local immunosuppressive environment of tumors, without affecting the tissular homeostasis of non-cancerous tissues, thus reducing the side effects of treatment.

Navarre participation



Universidad
de Navarra



Cima
Universidad
de Navarra



FUNDACIÓN PARA LA
INVESTIGACIÓN MÉDICA APLICADA

EU-JAV

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

3rd Health Programme

Summary

Development of specific tools to improve vaccination coverage in the EU and, therefore, the health of the population. Capitalize on the numerous existing initiatives and projects, to challenge and strengthen the European cooperation of Member States on vaccination, while contributing to sustainably integrate the achievements of EU-JAV in the health policies of European countries.

Navarre participation



Instituto de Salud Pública y Laboral de Navarra Nafarroako Osasun Publikoaren eta Lan Osasunaren Institutua

Gobierno de Navarra Nafarroako Gobernua



French partner

Institut National de la Santé et de la Recherche Médicale

APTITUDE

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

POCTEFA

Summary

APTITUDE aims to create a cross-border structuring framework for cooperation in the medical, social and technological care of the elderly, in accordance with the latest WHO recommendations and the concept of integrated and personalized care for the elderly.

Navarre participation



French partners

Centre Hospitalier Universitaire de Toulouse, Gérontopôle de Toulouse (seule structure de ce type labellisée par le Ministère de la Santé-France) and Équipe Régionale Vieillesse et Prévention de la Dépendance (ERVPD) d'Occitanie

eHealth - Navarra

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

CEF (Connecting Europe Facility)

Summary

Support Spain's efforts to be part of a secure peer-to-peer network that enables the exchange of Patient Summaries (SP) and Electronic Prescriptions (eP) through the Spanish National Contact Point for eHealth (NCPeH).

Navarre participation



BionicVEST

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Summary

Vertigo of vestibular origin has an overall prevalence of 38% in the elderly and deserves special attention because of the high risk of falls and permanent functional disability, and even death. This severely impairs their lives, making them unable to perform daily activities such as driving and even walking. This project will develop the first system to electrically reproduce linear accelerations in the otolithic organ by stimulating its neural endings. The project will consist of three phases: Device design, fabrication and clinical trial.

Navarre participation



CARAMBA

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Summary

CARAMBA aims to use revolutionary CAR-T cell technology to address multiple myeloma, a rare and incurable hematological malignancy. Myeloma is associated with a substantial socioeconomic burden and there is a strong demand from patients, their families and caregivers for curative treatment of myeloma. CARAMBA investigators will conduct a Phase I/II clinical trial of immunotherapy with patient-derived T cells that have been engineered to express a synthetic chimeric antigen receptor (CAR) specific for the myeloma antigen SLAMF7.

Navarre participation



Universidad
de Navarra

French partner

ARTTIC and Centre Hospitalier Universitaire de Lille

RESTORE

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Summary

Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the central nervous system for which there is currently no cure. The objectives of the project are to assess the safety and clinical feasibility and to demonstrate the first proof-of-principle therapeutic efficacy of antigen-specific tolerance-inducing dendritic cells (toIDC) in MS patients in two single-center clinical trials. All regulatory approvals have now been obtained.

Navarre participation



Universidad
de Navarra

Stance4Health

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme H2020

Summary

Stance4Health's overall goal is to develop a complete Smart Personalized Nutrition (SPN) service based on the use of mobile technologies, as well as the production of tailor-made foods that optimize gut microbiota activity and long-term consumer engagement.

Navarre participation



Universidad
de Navarra

SWEET

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme H2020

Summary

The SWEET project is designed to i) identify and address barriers and enablers to the use of sweeteners and sweet flavor enhancers (S&SE) and ii) examine the risks and benefits of using S&SE to replace sugar in the diet in the contexts of health, obesity, safety and sustainability. Industry experts will integrate technology, health and sweetness databases to provide a platform for selecting new and emerging S&SE to be included in food products. The behavioral and physiological impact of specific S&SEs will be examined in acute and repeated dosing studies and natural population differences (by age, region, gender, etc.) in sweetness perception will be established. A sensory profile will be developed and genetic determinants will be evaluated.

Navarre participation



Universidad
de Navarra

French partners

Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, ECRIN European Clinical Research Infrastructure Network, École Nationale Vétérinaire, Agroalimentaire et de l'Alimentation, Association Nationale des Industries Alimentaires and Vitagora Pole

NonChroRep



European programme

H2020

Navarre participation



Cima
Universidad
de Navarra

Summary

Recent findings implicate lncRNAs in the DNA replication process, representing a novel aspect of genome regulation that places lncRNAs in the spotlight of cancer biology. To further explore these findings the objectives are:

1. To identify the role of lncRNAs in chromatin replication.

2. To dissect the molecular mechanism by which lncRNAs function in this process.
3. To explore the role of these lncRNAs as cancer drivers and their potential as therapeutic targets.

EGAL-URG



European programme

POCTEFA

Summary

Creation of an operational network for cross-border cooperation in emergency and disaster medicine to ensure equal access to emergency care for the population.

Navarre participation



NAVARRABIOMED
CENTRO DE INVESTIGACIÓN BIOMÉDICA



Cruz Roja
Navarra



DYA



Universidad
de Navarra

Gobierno de Navarra Nafarroako Gobernua

French partners

Hôpital de Toulouse, Centre Hospitalier de Perpignan, Centre Hospitalier de Toulouse, Centre Hospitalier Intercommunal du val d'Ariège, Centre Hospitalier Ariège Couserans, Association médicale transpyrénéenne, Université Paul Sabatier Toulouse 3, Hospital Nostra Senyora de Meritxell. Centre Hospitalier de la Côte Basque, Centre Hospitalier de Bigorre and Centre Hospitalier de Pau

LGMed

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

POCTEFA

Summary

This project aims to promote innovation in the Aquitaine-Euskadi-Navarre area through collaboration between companies, technology centers, universities, hospitals and other agents in the region.

LGMed stems from the work carried out in HEALTH LSR (development of liquid silicone medical devices and creation of a related hub), and COMPETITIVEKO (creation of the medical devices hub "Innovmedica Alliance").

With this new project, the partners intend to continue to promote innovation in the health-care sector, and more specifically in the field of medical devices.

Navarre participation



Universidad
de Navarra

ain

French partners

Université de Pau et des Pays de l'Adour,
Centre Hospitalier Universitaire de Toulouse
and Chambre de Commerce et d'Industrie
Bayonne Pays Basque

DIABFRAIL-LATAM

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Summary

DIABFRAIL-LATAM aims to scale up a multi-modal intervention in older people with diabetes who are highly vulnerable due to their vulnerable status. The project is clearly aligned with the programs of many of the institutions that constitute the Global Alliance for Chronic Diseases (GACD), including DG Research&Innovation of the European Commission, with projects supported by GACD, with several actions of the EIP-AHA initiative and with strategies on chronic non-communicable conditions in the EU, in several countries of the Latin American and Caribbean Region, PAHO and WHO.

Navarre participation

upna

Universidad Pública de Navarra
Nafarroako Unibertsitate Publikoa

French partner

Motac France

Palliative Sedation

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme
H2020

Summary

Due to the increase in cancer and multiple chronic diseases, the number of patients with refractory symptoms, i.e. severe symptoms where conventional treatment options fail, is likely to increase. In these cases, palliative sedation (PS), which is the intentional lowering of consciousness at the end of life, may be indicated. However, PS is too often limited to continuous deep sedation and is confused with hastening death. This proposal offers a modified concept, namely, proportional PS, with titration of sedatives to the point of symptom control to improve patient comfort.

Navarre participation



Universidad
de Navarra

ain

PRECODE

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme
H2020

Navarre participation



Universidad
de Navarra

Summary

While pancreatic cancer is the eleventh most common cancer worldwide, it is the seventh leading cause of cancer-related deaths. Despite advances in its diagnosis and management, the five-year survival rate is still less than 10%. The PRECODE training network is taking advantage of a newly developed technique, the self-assembly of functional organ-mimicking tissues, to accelerate drug development for this lethal disease. Young researchers are honing their skills in culturing and manipula-

ting pancreatic organoids to better understand the progression of the disease. Ultimately, the use of pancreatic organoids created from the patient's own cells could lead to targeted, specific and extremely effective personalized medicine against pancreatic cancer.

ViroPedTher

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Summary

Integrate clinical and laboratory research to develop tumor-targeted oncolytic adenoviruses with the ability to elicit a therapeutic immune response in those tumors.

Navarre participation



Universidad
de Navarra

Action Grant to Support Increase Capacity for the Collection of COVID-19 Convalescent Plasma in the North of Spain

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

EU4Health

Summary

It is intended to increase the capacity of transfusion centers for the collection, storage and testing of plasma from convalescent COVID-19 patients through investment in equipment and other associated needs.

Navarre participation



French partners

Université Sorbonne, INSERM, Institut Pasteur, Santé Publique, Université de Corse Pascal Paoli and Epiconcept

LINKER

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020 - MSCA

Summary

Genes and their corresponding pathways form networks that regulate several critical cellular functions in tumor development. To unveil transcriptional changes, this project will develop a recent and efficient computational method, called LINKER, which aims to discover GRNs from RNAseq data; and, given these networks, to develop efficient differential network analysis methods that shed light on phenotype-associated regulatory changes.

Navarre participation



Cima
Universidad
de Navarra

SyLeNCe

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020 - MSCA

Summary

A systems biology approach based on single-cell, low-input RNA sequencing of bone marrow niche populations is proposed in order to establish not only the molecular landscape of the cells that make up the stem cell niche in the homeostasis and disease, but also the lineage relationships that may exist between cells in the stroma. Using the mouse bone marrow niche during neoplastic transformation to acute myeloid leukemia (AML), we will first unravel the cellular and molecular interactions that constitute the tumor microenvironment during disease development and progression using multiparametric flow cytometry and sequencing. RNA.

Navarre participation



Cima
Universidad
de Navarra

TokiJan

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

Euroregion Nueva
Aquitaine-Euskadi-
Navarre

Summary

A project based in healthy eating.

Navarre participation



French partners

Communauté d'Agglomération Pays Basque,
Nouvelle-Aquitaine, LAN-EKO and Nouve-
lle-Aquitaine

I-MOVE-COVID-19

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Summary

I-MOVE-COVID-19 aims to obtain epidemiological, clinical and virological information on COVID-19 and SARS-CoV-2 infected patients by providing a flexible surveillance platform (adaptable to the epidemiological situation), research studies, hypothesis testing and evaluation of public health interventions (e.g. vaccination, antivirals) in order to contribute to the knowledge base, guide patient management and inform the public health response. To this end, the influenza surveillance network (I-MOVE), which has long existed across Europe, will be adapted and expanded to include COVID-19. The network includes primary care networks, hospitals and health centers. The network includes primary care networks, hospitals and national laboratory reference centers in eleven countries.

Navarre participation



French partners

Epiconcept, Université de Corse Pascal Paoli, Sorbonne Université, Agence Nationale de Sante Publique, Institut Pasteur, Institut National de la Sante et de la Recherche Médicale, Assistance Publique Hôpitaux de Paris, Agrah, Centre Hospitalier Universitaire Montpellier, Centre Hospitalier Universitaire de Rennes and Hospices Civils de Lyon

OPTIMAGE

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme POCTEFA

Summary

The exchange of experiences between the territories and the various members makes it possible to raise awareness among professionals about optimizing the therapeutic management of elderly patients. The pharmacists involved in the project are participating in the reinforcement of medication reconciliation and in the deployment of pharmaceutical interviews for elderly and polymedicated patients.

Navarre participation



French partner

Centre Hospitalier Universitaire de Toulouse

VASADIN

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme Euroregion Nueva Aquitaine-Euskadi-Navarre

Summary

The main objective of this project is to define a health care model for the elderly that generates value by responding to the real needs and health outcomes valued by this population group. This objective is broken down into the following specific objectives:

1. To describe the models of care for the elderly currently in place in the three regions that make up the Euroregion.
2. To identify the elements of success of the models studied.
3. To identify the aspects not covered by the models studied.
4. To select products, services and technologies capable of contributing to the deficit areas described.
5. To identify the key components of a value-based, comprehensive and flexible model of care for the elderly considering the aspects previously analyzed.

Navarre participation



French partners

Alliance Innovation Santé Nouvelle-Aquitaine and Autonom'Lab

BILEBANK

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

Euroregion Nueva Aquitaine-Euskadi-Navarre

Summary

The goal of the BileBank project is to establish a common and functional biobank of human bile samples available for use in liquid biopsy and personalized medicine strategies to promote research in hepatobiliopancreatic diseases.

Navarre participation



French partner

Université de Bordeaux

RETSASO

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

POCTEFA

Summary

Cross-border cooperation network in the health and social field.

Navarre participation



French partners

Université de Perpignan Via Domitia, Etcharry Formation Développement, Centre Régional de Formation aux Métiers du Social - E.R.A.S.M.E. and FAIRE Économie Sociale et Solidaire

CARDIOPATCH

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

SUDOE

Summary

Network of Excellence for the development of advanced therapies for the treatment of myocardial infarction based on regenerative medicine and 3D printing.

Navarre participation



Clínica
Universidad
de Navarra



Cima
Universidad
de Navarra



SODENA
DESARROLLO DE NAVARRA
NAFARROAKO GARAPENA



French partners

Centre Hospitalier Universitaire de Toulouse
Département Cardiologie, Université de Montpellier (UM) - Institut des Biomolécules Max Mousseron and Association pour les Patients Insuffisants Cardiaques (ASPIC)

B2-InF

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Summary

Assisted reproductive technology (ART) plays an important role in the reproductive health of European society and is a rapidly growing part of the healthcare industry. In this context, B2-InF will seek to answer two questions: (1) How do young people perceive and think about ART; (2) How can ART clinics better adapt their research, services and information to the opinions, concerns and expectations of citizens; By answering these questions, B2-InF aims to promote public participation in the science and delivery of ART to make ART more responsive to society's needs and concerns.

Navarre participation



Universidad
de Navarra

HARMONY PLUS

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Summary

HARMONY PLUS leverages the capabilities of the HARMONY Big Data platform to address unmet needs, expanding its scope to incorporate myeloproliferative neoplasms, including chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis; and lymphoproliferative disorders, including Hodgkin's lymphoma, Waldenström's macroglobulinemia and all other rare MH not covered by the HARMONY Project.

Navarre participation



Universidad
de Navarra

MEPHOS

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Navarre participation



Universidad
de Navarra

Summary

Osteoarthritis, the most common form of joint disease affecting millions of people worldwide, occurs when the protective cartilage that cushions the ends of bones wears away over time. Most commonly, the disease affects the joints of the hands, knees, hips and spine, often requiring arthroplasty. It is currently an incurable disease and only symptomatic treatment is available. The EU-funded MEPHOS project aims to develop a novel integrated strategy for the treatment of osteoarthritis, based on the intra-articular deposition of polymeric microplates that provide long-term drug the-

rapy and mechanical support simultaneously. The polymeric microplates constantly release algological drugs and combine molecules and biological products in order to prevent tissue degeneration by inducing regeneration processes. The project is a collaborative work of seven academic institutions and industrial partners, both European and American, for manufacturing, biological and preclinical evaluation.

AND-PD

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Summary

Using mental comorbidity models of Parkinson's disease, AND-PD will investigate functional changes in brainstem nuclei and establish the link to the anxiety phenotype. Findings will be used to inform preclinical (rodent, non-human primate and biobank samples) and clinical (fMRI and PET imaging, behavioral analysis, retrospective cohort analysis) research to identify and correlate causalities between dysfunctional neurocircuitry and PD comorbid anxiety.

Navarre participation



FUNDACIÓN PARA LA
INVESTIGACIÓN MÉDICA APLICADA



Cima
Universidad
de Navarra

French partners

Université de Bordeaux and Motac France

CRUCIAL

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Summary

CRUCIAL's goal is to provide physicians with diagnostic tools and pharmaceuticals with therapeutic pathways targeting microvascular health in order to prevent the progression of cognitive and cardiac disease, reduce morbidity and ultimately improve patients' quality of life.

Navarre participation



Universidad
de Navarra



FUNDACIÓN PARA LA
INVESTIGACIÓN MÉDICA APLICADA



Cima
Universidad
de Navarra

BRAV3

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme H2020

Summary

The overall concept is to provide durable functional support to injured hearts by fabricating customized regenerative biological ventricular assist devices (BioVADs) based on advanced tissue engineering. To this end, we will apply multimodal deep cardiac phenotyping coupled with advanced computational modeling and biomechanical analysis on a large animal disease model to create a customized 3D printable design.

Navarre participation



Universidad
de Navarra



DECISION

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme H2020

Summary

DECISION will improve the understanding of the pathophysiology of cirrhosis decompensation by integrating high-throughput multi-omics profiling results with comprehensive clinical data from 2,200 fully characterized patients (over 8,600 time points) with available standardized biological samples. Second, novel combinatorial therapies for patients with decompensated cirrhosis to prevent death will be identified. These therapies will be refined in new and/or optimized animal models and then test the best combination in high-risk patients in a Phase II clinical trial constructed in DECISION. Third, two tests will be developed: one to predict the outcome of patients with cirrhosis decompensation when treated with standard therapy (prognostic test); and one to identify patients who will respond to the new combinatorial therapy (response test).

Navarre participation



NAVARRABIOMED
FUNDACIÓN MIGUEL SERVET

French partners

CEA, Institut National de la Santé et de la Recherche Médicale, Assistance Publique Hôpitaux de Paris, AGRAH and UPCITÉ

ISOLDA

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Summary

ISOLDA will seek to improve the efficacy of current seasonal influenza vaccines up to a staged Phase I clinical trial with a lead immunomodulatory compound selected from ex vivo and in vivo studies, which will be added to current vaccine formulations. ISOLDA will further build on new generation MERS vaccines, such as replication-competent and spread-deficient replicons and MVA-MERS S recently developed by ISOLDA partners.

Navarre participation



Universidad
de Navarra

cONCReTE

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020 - MSCA

Summary

RISE- cONCReTE will undertake an integrated approach to reveal novel functional links between ncRNAs and oncogenic pathways. To this end, the project will:

- Characterize novel classes of tumor-associated ncRNAs.
- Investigate the impact of ncRNAs on key aspects of tumor cell biology.
- Develop payloads (e.g., aptamers) to deliver therapeutic ncRNA derivatives to specific cancer cell types.

Navarre participation



FUNDACIÓN PARA LA
INVESTIGACIÓN MÉDICA APLICADA



Cima
Universidad
de Navarra

SOPHIA



European programme H2020

Summary

SOPHIA will change attitudes and the experience of obesity by demonstrating the heterogeneity of the disease, identifying people at risk of complications, determining the best treatment for each individual, providing a common vocabulary and shared understanding of obesity, demonstrating shared value, combining commercial opportunity with social benefit.

Navarre participation



Universidad
de Navarra

French partner

Centre Hospitalier Regional et Universitaire
de Lille

HEALIKICK



European programme H2020

Summary

The goal of this project is to offer next-generation bone injector materials for the repair of large critical defects. Bioengineered bone graft systems must be able to guide the regrowth of new bone in important gaps, which is why implants pre-seeded with mineralizing cells are of great clinical interest.

Navarre participation



Universidad
de Navarra

ARDAT

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Summary

The overall objective is to analyze currently available clinical data and then design preclinical and clinical studies to fill knowledge gaps in the development of advanced therapies. Our main objectives are:

- 1) To develop improved model systems to predict the immunogenicity of products in humans. This will be achieved by generating 3D human and NHP liver models.
- 2) To improve our understanding of gene/cell therapy drug metabolism within a range of cell types. The plan is to define the metabolism of the therapeutic vector genome in different cell types to understand whether the rates of degradation, episomal maintenance or integration, and metabolic stress induced by AAV vector transgene expression vary from cell to cell. We will then adopt strategies to mitigate vector genome loss and improve persistence.
- 3) To use diverse clinical expertise to establish the clinical factors around pre-existing immunity that limit patient access to therapy for advanced therapies.
- 4) To engage regulators to ensure that the concepts and data generated through this IMI program will fill gaps and support future trials.

Navarre participation



French partners

Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Institut National de la Santé et de la Recherche Médicale, Sanofi-Aventis Recherche et Développement S.A., Institut du Cerveau et de la Moelle Epinière, Association Genethon, Genosafe Sas, and Lysogene

HERA Incubator

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

HERA-HE

Summary

Improvement and strengthening of national whole genome sequencing (WGS) and/or reverse transcription-polymerase chain reaction (RT-PCR) infrastructures and capacities to respond to the COVID-19 pandemic in the EU and the European Economic Area.

Navarre participation



HEALCIER

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

POCTEFA

Summary

HEALCIER aims to contribute to improving the competitiveness of the healthcare sector by applying the Circular Economy.

Navarre participation



French partner

Ecole Supérieure des Technologies Industrielles Avancées

Xsleeve



European programme

HERA-HE

Summary

Cystoscopy is considered a semi-invasive procedure and one of the main associated risks is infection of the bladder or urinary tract. This is the reason for the present project, the development of a sheath to cover the cystoscope in order to avoid infections. In line with the Euroregion, the aim of the project is to respond to a real need of healthcare personnel, allowing them to save time.

Navarre participation



French partner

Olaberria - Aquitania

ECLiCare



European programme

Euroregion Nueva
Aquitaine-Euskadi-
Navarre

Summary

Development of new products and services based on personalized diagnostic devices for elderly people, supported by information technologies such as artificial intelligence, Big Data and communications. The project will explore the capability of smartphones as an instrumental platform for ECL-based molecular diagnostic tests.

Navarre participation



French partner

Université de Bordeaux

JA ImpleMENTAL



European programme

3rd Health Programme

Summary

Transfer and pilot implementation of actions aimed at suicide prevention (selected elements of the Austrian best practice on suicide prevention PS "SUPRA").

Navarre participation



French partner

Ministère des Affaires Sociales et de la Santé

SISAQOL-IMI



European programme

H2020

Summary

Measuring and quantifying how a patient feels or functions during treatment is an important endpoint in cancer clinical trials. It is generally accepted that the collection of PRO data in cancer clinical trials allows the patient's voice to be included in the risk/benefit assessment of therapies. The initiative aims to find consensus on appropriate methods for analyzing valid PRO objectives in randomized clinical trials (RCTs) in cancer and ways to communicate these PRO results in a standardized way that is understandable to all.

Navarre participation



ARCADIAN-IoT

2015

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Summary

The use of the Internet of Things (IoT) is constantly growing. However, cyber-attacks, hijacking programs and cyber-incidents are also on the rise. Currently, cybersecurity practices do not address these incidents. The implementation of new technologies could increase the frequency and complexity of such incidents, posing a danger to IdC users around the world. The goal of the EU-funded ARCADIAN-IoT project is to overcome this problem by developing an advanced framework that enables greater security, trust and privacy in IoT systems, while providing users with better control over their privacy with more transparency.

Navarre participation



Universidad
de Navarra

TRiAnkle

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

H2020

Summary

To bridge the critical gap of suitable treatments, TRiAnkle proposes to develop 3D bioprinted scaffolds based on collagen and gelatin, functionalized with stem cells and/or nanoencapsulated regenerative factors. Surgical implantation of these novel functionalized biomaterials will allow targeted delivery of the aforementioned biologically active agents to promote cell growth and differentiation to enable better and faster regeneration of injured collagen-rich tissues such as articular cartilage, ligament and tendon of the ankle.

Navarre participation



DESTINATION



European programme H2020

Summary

DESTINATION will generate a smart library of (a) programmable RNano scaffolds for packaged mRNA binding and (b) RNA aptamers for targeted laser internalization of RNanos into cells. The most promising candidates will be tested in vitro, and the leading ones will be moved to new animal models. Ultra-high resolution imaging will enable technology assessment, with an iterative R&D approach aimed at demonstrating 3 revolutionary preclinical proof of concept, including in the attractive field of CAR-T cancer immunotherapies.

Navarre participation



FUNDACIÓN PARA LA
INVESTIGACIÓN MÉDICA APLICADA



CIMA
Universidad
de Navarra

T2EVOLVE



European programme H2020

Summary

The overall objective is to develop an innovation ecosystem to accelerate the development process of genetically modified T-cell therapies in the EU. The project will provide novel tools for education and improved communication between healthcare professionals and patients, optimized laboratory models to help determine the safety and efficacy of new therapies with modified T cells, standardized methods for the production and monitoring of these therapies during treatment, etc.

Navarre participation




Universidad
de Navarra

French partners

Institut National de la Santé et de la Recherche Médicale, Institut de Recherches Internationales Servier Iris and Institut National du Cancer GIP

RESPIRE



European programme

Horizon Europe- EIC


Summary

Palobiofarma is a Spanish biotech company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation. Our compound PBF-680 is the first therapy of its kind with disease-modifying effects in respiratory diseases such as COPD.

Navarre participation



NONCO-MICROTIS



European programme

H2020 - MSCA

Summary

NONCO-MICROTIS will combine new discoveries in long non-coding RNA (lncRNA) biology with cutting-edge research to uncover innovative therapeutic opportunities for the treatment of lung cancer, one of the most prevalent and deadly cancers worldwide. NONCO-MICROTIS will investigate the senescence-related functions of small peptides produced by TIS-lncRNAs, which will be harnessed to target these unique cells in lung tumors.

Navarre participation



X-PAND

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

Horizon Europe - EIC

Summary

Hematopoietic stem cells (HSCs) are an elusive cell type, whose presence can only be deduced retrospectively, based on the outcome of time-consuming transplantation experiments. Since the current state of the art does not allow prospective identification of HSCs, current cell and gene therapy technology has been optimized mainly with surrogate progenitor cells, which differ biologically from HSCs. The technological breakthrough of this approach is to capture HSCs in ex vivo cultivation, which is achieved through a combination of innovative expansion conditions, iterative cell sorting, and individual multiomic cell profiling. Rapid, quantitative and qualitative in vitro assessment of HSCs predictive of in vivo function may become a sustainable alternative to xenotransplantation experiments in mice.

Navarra participation



Universidad
de Navarra



NAVARRABIOMED
FUNDACIÓN MIGUEL SERVET

AAVolution

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

Horizon - EIC

Summary

Liver-targeted gene therapy has undergone significant development in the last two decades. Recombinant adeno-associated vectors (AAVs) are the vectors of choice for liver gene transfer and have recently reaped remarkable successes in clinical trials. AAVolution will significantly expand the toolkit for AAV-mediated liver gene therapy, developing novel and improved molecular tools to address the most relevant hurdles towards safer and more effective therapies, and provide access to treatment for patients currently excluded from clinical trials.

Navarra participation



FUNDACIÓN PARA LA
INVESTIGACIÓN MÉDICA APLICADA



Cima
Universidad
de Navarra

IRIS

2015 16 17 18 19 20 21 22 23 24 25 26 27 28 2029

European programme

Europa Digital

Summary

IRIS contributes to the acceleration of digital transformation and innovation in Navarra, acting as a catalyst and ONE STOP SHOP for the digitalization of the region, through the efficient provision of services, the effective management of its resources and the generation of spaces for collaboration with key public-private agents.

Navarre participation



DRIMMS

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

Horizon - MSCA

Summary

Myelodysplastic syndromes (MDS) are heterogeneous clonal hematopoietic neoplasms that affect the elderly. This project hypothesizes that dysfunctions in the immune microenvironment favor clonal expansion and disease progression in the early stages of MDS and, therefore, therapeutic approaches that enhance the immune response in patients with CCUS or MDS may effectively prevent or halt disease onset.

Navarre participation



EPINPOC

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

Euroregion Nueva
Aquitaine-Euskadi-
Navarre

Summary

Epitopes are small regions of proteins in viruses and bacteria that can be recognized by antibodies. The discovery of these recognition sequences is crucial for designing point-of-care diagnostic devices for antibody detection. The generation of artificial epitope libraries for the selection of epitopes against certain antibodies can overcome this problem, since the definition of these molecular recognition sequences simply from pathogen information is not straightforward. This project proposes a method based on bioinformatics tools and droplet microfluidics to identify short amino acid sequences that specifically bind to the parasites of different antibodies. For this purpose, machine learning algorithms will be applied to epitope databases to reduce the diversity of our libraries. These libraries will be fused to a GFP and encapsulated in water-in-oil droplets. Epitope-antibody recognition will be measured by increasing the fluorescence anisotropy of the complex. Finally, epitope selection will be performed by fluorescence activated droplet sorting (FADS).

Navarre participation



French partner

CNRS Université de Bordeaux

ELMUMY

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme ELMUMY

Navarre participation



Universidad
de Navarra

Summary

Multiple myeloma is a chronic malignancy characterized by slow progression and recurrences. Currently, there is no effective cure, as the disease eventually develops resistance to all available therapeutic approaches. Despite recent advances that have broadened our understanding of the cellular functions associated with the transition from health to disease, recurrence and response to therapy, critical aspects of this complex pathology have yet to be elucidated.

The application of omics technologies and bioinformatics approaches on highly annotated samples obtained from all informative states (monoclonal gammopathy of undetermined significance [MGUS], latent multiple myeloma [LMM], active multiple myeloma [MM]) could identify the biological pathways and molecules responsible for the onset, progression and therapy resistance of Multiple Myeloma. In parallel, special emphasis will be given to elucidating the health determinants and risk factors associated with progression to active MM from MGUS/MML by using extensive demographic, lifestyle and exposure datasets.

MGUS is present in 3-5% of the aging European population and each year, 1% progress to an incurable MM that imposes a signifi-

cant burden on EU societies and healthcare systems. Therefore, the best chances of curing MM may lie in preventing its progression in the first place. In addition, experimental models that recapitulate myeloma progression are needed.

An interdisciplinary approach that brings together clinicians and researchers with the goal of integrating epidemiological, clinical, and experimental data sets to create a molecular model of cellular processes associated with the onset of active MM and response to therapy is proposed. The proposed systems medicine approach could generate clinically applicable molecular features that could improve the management of MM patients. In addition, the integration of lifestyle, clinical, and omics information will provide patient-specific profiles that will enable personalized diagnosis, prevention, and therapeutic approaches.

BionicVest-2

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

Horizon Europe

Navarre participation



Universidad
de Navarra

Summary

BIONICVEST-2 presents a solution to restore balance and prevent falls through vestibular implantation and electrical stimulation of the otolith organ. Worldwide, approximately 684,000 people die each year due to falls and 37.3 million falls require medical attention. The medical cost to treat falls in the EU is approximately €25 billion each year. This number is expected to increase as the population of older people is growing. One of the most important causes of falls is vestibular dysfunction. Therefore, restoration of vestibular function could revolutionize this field, as it offers a complete new treatment paradigm. The foundation for the treatment of vestibular dysfunction was laid during the EU-funded BionicVEST H2020 FET-OPEN project. This FET-OPEN project achieved spectacular results and demonstrated that it is possible to successfully restore vestibular function by electrical stimulation of the otolith organ. Where there was no adequate treatment before, it is now feasible to improve and even restore balance. The outcome of this first BionicVEST FET-OPEN project was

a proof of concept in humans with a prototype otolithic vestibular implant. To unlock the full commercial potential of this vestibular restorative therapy, the new BionicVEST-2 project will focus on the path to commercialization of the BionicVEST implant. This requires improvements in the implant technology to reach its full market potential. A pivotal clinical trial will be conducted with the new device to provide evidence of the safety and efficacy of the final implant, as well as to collect data for health economics. In addition, novel clinical diagnostic tools will be developed to identify patients who can benefit from this technology quickly. In-depth market research and an elaborated business case should confirm that the vestibular implant will bring the long-awaited solution for vestibular disorders and ameliorate the enormous societal impact of this problem.

SOLACE

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

EU4Health

Summary

SOLACE will assess the current status, needs and best practices of lung cancer screening in the EU Member States and develop a comprehensive package of guidelines and implementation measures covering all stages of the lung cancer screening process: evidence-based guidelines, technical documents, standard operating procedures, quality assurance documents, methodology, benefit-harm balance and cost-effectiveness. This package will be used to demonstrate de novo implementation.

Navarre participation



Universidad
de Navarra

French partners

Assistance Publique Hôpitaux de Paris
and Hospices Civils de Lyon

IMMUTOL

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

Horizon Europe

Navarre participation



Universidad
de Navarra

Summary

Autoimmune diseases are currently treated with immunosuppressive and supportive therapies, which reduce inflammation but do not stop the cause of the disease and are necessary for life. Therefore, there is an unmet need for safe and effective therapies for these diseases that are well tolerated and target the cause of the disease. Tolerogenic dendritic cell (DC)-based therapies offer the potential to restore immune regulation, leading to long-lasting effects. Tolerogenic DCs modified with vitamin (Vit) D3 have recently been applied to multiple sclerosis (MS) patients in phase I trials, demonstrating safety, tolerability, feasibility and preliminary evidence of an effect. Molecular characterization of VitD3DCs in MS patients suggests that they possess lower tolerogenic properties than healthy individuals. Therefore, correcting these deficiencies through gene transfer could improve their effectiveness.

The goal of IMMUTOL is the rapid development and validation of an advanced therapeutic medicinal product (ATMP) based on VitD3-modified tolerogenic DCs for immunotherapy approaches. Through a multidisciplinary approach, IMMUTOL will harness the power of tolerogenic VitD-3DC-based immunotherapy to develop a more potent and durable treatment for MS and, in turn, other inflammatory autoimmune diseases with unmet medical needs. In parallel, it will provide information on tolerance mechanisms and patient-specific requirements for the manufacture of effective tolDC products. The results will lead to the design of a clinical protocol in accordance with regulatory requirements for first-in-human application of modified tolerogenic VitD3DCs in MS patients.

RELECOV

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

HERA-HE

Summary

Consolidation of WGS and RT-PCR activities for SARS-CoV-2 in Spain towards sustainable use and integration of improved infrastructure and processes in the RELECOV network.

Navarre participation



UNATI

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

Horizon Europe

Summary

Europeans are the largest consumers of alcohol.

We propose a 4-year clinical trial with >10,000 drinkers, to reduce alcohol-associated harms will be randomized in a 1:1 ratio to 2 advice: 1) abstinence; 2) moderation (≤ 7 drinks/week (women) and ≤ 14 drinks/week (men)), and avoidance of binge drinking, with preferential consumption of red wine with meals, and consumption spread throughout the week. The hypothesis is that moderate consumption is not inferior.

Navarre participation



Universidad
de Navarra

ARISTOS

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

Horizon Europe MSCA

Summary

ARISTOS aims to be the next Postdoctoral Program in Biomedicine and Health Sciences cofunded by the Horizon Europe Marie Skłodowska-Curie COFUND scheme and the Consorcio Centro de Investigación Biomédica en Red M.P. (CIBER) in Spain. With a total duration of 60 months, it will offer 27 postdoctoral positions for three years each, at CIBER groups led by distinguished principal investigators.

Navarre participation



JAMRAI II

2015 16 17 18 19 20 21 22 23 24 25 26 27 2028

European programme

EU4Health

Navarre participation



Summary

Antimicrobial resistance (AMR), particularly to antibiotics, has emerged as a serious cross-border health threat with the potential to undermine modern medicine. In the EU, antibiotic resistance is responsible for at least 33,000 deaths, 2.5 million extra days of hospitalization and an estimated societal cost of about €1.5 billion per year. Combating AMR requires a comprehensive approach combining awareness, surveillance, antimicrobial stewardship, and infection prevention and control, while ensuring access to antibiotics

and diagnostics. These interventions should be based on a “One Health” perspective, taking into account the interconnectedness between humans, animals and the environment. Following the 2017 EU One Health Action Plan against AMR to make Europe a best practice region and the first European Joint Action (JA) on AMR and healthcare associated infections (EU JAMRAI), this new JA, EUJAMRAI 2, will support Member States / Associated Countries (MS / CA) in their efforts to develop and update their National Action Plan (NAP) on AMR.

**MAIN FUNDING
OPPORTUNITIES FOR
BIOHEALTH PROJECTS
IN CROSS-BORDER
AND EUROPEAN
COOPERATION**



EUROREGION NEW AQUITAINE, EUSKADI, NAVARRA

www.euroregion-naen.eu/es/

New Aquitaine, Euskadi, Navarre, three regions, two countries, one territory: a common area of cooperation to promote projects contributing to the economic, social and cultural development of the Euroregion on a cross-border, interregional and European scale.

Eligible territory

New Aquitaine, Basque Country, Navarre

Funds*

1- Annual call for applications for Euroregional citizenship grants (March). 500.000 €

Priorities: culture, education, youth, sport, contemporary social challenges and multilingualism.

2- Annual call for knowledge economy grants (September). 400.000 €

Priorities: aeronautics, aerospace, advanced manufacturing, automobile, agriculture and agri-food industry, health, biohealth, silver economy, renewable energies, marine and coastal resources, sustainable construction and wood.

Funding rate

50% (the project must be at least 20% self-financed).

Profile of the beneficiary entity

Legal entities, public or private, self-employed and/or individual entrepreneurs.

Other financial tools


Strategic partnerships: structuring projects that converge with the Euroregional strategy, not subject to competitive bidding, and which are submitted for approval to the Euroregion's bodies (management, executive committee and assembly). Funding, limited to three years, averages 40,000 euros/year.

Type of partnership

The partnership must include at least one partner from each of the three territories.

*The figures are from the last call for proposals: the budget allocation is approved annually.





POCTEFA

www.poctefa.eu/

POCTEFA 2021-2027 is the acronym of the INTERREG VI-A Spain-France-Andorra Program. It is a European territorial cooperation program created to promote the sustainable development of the border territory between the three countries.

Managing Authority

Consortium of the Working Community of the Pyrenees (CTP) based in Jaca (Huesca).

Eligible territory

Spain: Araba, Gipuzkoa, Bizkaia, Navarra, La Rioja, Huesca, Zaragoza, Barcelona, Girona and Lleida.

France: Pyrénées-Atlantiques, Ariège, Haute-Garonne, Pyrénées-Orientales and Hautes-Pyrénées.

Andorra: All the territory.

Funds for the period 2021-2027

243,079,964 € (including program technical assistance).

Funding rate

65% (with exceptions for entities and activities subject to State Aid).

Goals

Innovation and digital transformation, ecological values, social values, the structuring of the cross-border area, governance.


Profile of the beneficiary entity

Entities or bodies with legal personality, of both public and private nature (private companies, public entities, and non-profit entities).

Type of partnership

The partnership must be formed by partners from at least two states (ES-FR-AND). The main beneficiary must be from Spain or France.





SUDOE

www.interreg-sudoe.eu/

The Interreg Sudoe Program (short for Interreg VI-B Southwest Europe Cooperation Program) supports regional development in southwest Europe by financing transnational projects through the ERDF Fund.

Managing Authority

Government of Cantabria based in Santander

Eligible territory

Spain: all the autonomous communities and autonomous cities, except for the Canary Islands.

France: the regions of New Aquitaine and Occitanie and for the region of Auvergne-Rhône-Alpes, the former region of Auvergne.

Mainland Portugal.

Andorra participates as a third country.

Funding rate

75%

Goals

Address common issues on research and development, competitiveness of small and medium-sized enterprises, climate change and environmental risks, etc.

Profile of the beneficiary entity

Entities or organizations with legal personality, of both public and private nature (private companies, public entities and non-profit organizations).

Type of partnership


The partnership must be formed by partners from at least two of the participating countries, one of which must be from an EU member state.

Funding for the period 2021-2027

107.1 million

Interreg
Sudoe





ATLANTIC AREA

www.atlanticarea.eu

The Interreg (VI-B) Atlantic Area Program supports transnational cooperation projects in the Atlantic regions of 4 countries to respond to regional challenges in the field of innovation, resource efficiency, environment, and cultural assets, supporting regional development and sustainable growth.

Managing Authority

Regional Council of the North (Portugal) based in Porto

Eligible territory

Spain: Galicia, Principality of Asturias, Cantabria, Basque Country, Community of Navarre, La Rioja, Andalusia and the Canary Islands.

France: Basse-Normandie, Haute-Normandie, Pays de la Loire, Bretagne, Aquitaine, Limousin and Poitou-Charentes.

Ireland: Northern and Western, Southern and Eastern and Midland.

Portugal: Norte, Algarve, Centro (PT), Lisbon Metropolitan Area, Alentejo, Regiao Autónoma dos Açores and Regiao Autónoma de Madeira.

Funds for the period 2021-2027

113,075,964 €

Funding rate

75%

Goals

Blue innovation for competitiveness, blue environment, a more social Europe, governance.

Profile of the beneficiary entity

Entities or bodies with legal personality, of both public and private nature (private companies, public entities and non-profit entities).

Type of partnership

The partnership must be formed by partners from at least two participating countries, of which at least one will be a beneficiary from an EU Member State.





HORIZON EUROPE

Goal

To achieve scientific, technological, economic and societal impact of EU investments in research and innovation, thereby strengthening its scientific and technological bases, fostering European competitiveness and driving the systemic changes needed to ensure a green, healthy and resilient EU.

Implementation

Through thematic subprograms, structured in 3 pillars:

- Excellent Science
- Global Challenges and European Industrial Competitiveness. One of the defined clusters is Health.
- Innovative Europe

Each pillar publishes biannual work programs, where the themes of the projects to be funded are specified. The calls are annual with deadlines for submission of proposals of 3 to 5 months.

These are R&D projects addressing societal challenges, industrial leadership, recovery, green and digital transitions.

It is implemented through R&D project grants (between 50 and 100% funding), awards and recruitment of research excellence.

Participants

Any legal entity (company, university, research center, association, public administration...) that wants to develop an R&D project. Consortium projects: at least 3 entities from 3 different States. Individuals (entities or individuals): research, mobility and training actions, and coordination and support actions.



EU4HEALTH

Goals

- Improving and promoting health in the EU
- Protecting people from severe cross-border threats to health
- Improving access to medicines, health products and products of interest to crises
- Strengthening health systems, their resilience and resource efficiency

Type of projects

It supports a wide range of actions and initiatives in four areas: crisis readiness, disease prevention, health systems and workforce, and digitization. Cancer is a major priority in all four strands.

Content


- Prevent diseases and promote health and international health cooperation.
- Support actions to prevent, prepare for, and respond to cross-border health threats.
- Supplement national stockpiles of essential crisis products and create a reserve of medical, health and support personnel.
- Contribute to the digitization of healthcare, medical innovation, and equal access to healthcare.
- Support evidence-based decision making.

Implementation

It is implemented by member states and non-governmental and international organizations, which can apply for EU funding in the form of grants, prizes and public procurement, as well as through indirect management by the European Commission and executive agencies. It is implemented through annual work programs.

Participants

All types of entities and individuals located in a European or associated country: academia and research, SMEs, public administration, NGOs, etc.



DIGITAL EUROPE

Goals

- Drive digital transformation and accelerate the EU's economic recovery.
- Support the implementation of digital technologies used by citizens, businesses and administrations.

Contenido

Refuerzo de competencias digitales avanzadas en los ámbitos de la informática de alto rendimiento, la analítica de macrodatos, la ciberseguridad, la robótica y la inteligencia artificial. Abarca 5 ámbitos decisivos:

- High Performance Computing.
- Artificial intelligence.
- Cybersecurity and trust.
- Advanced digital skills.
- Deployment, better use of digital capabilities and interoperability.

Type of projects

- Acquisition of high-performance computing machinery.
- Establishment of data spaces and artificial intelligence test sites
- Establishment of cybersecurity centers
- Master's degrees for the use of advanced digital technology
- Deployment of a digital innovation network
- Offering to public and private institutions

Implementation

Grants and tenders managed by the Commission, the European High-Performance Computing Joint Undertaking and the European Cybersecurity Competence Centre.

Participants

All types of entities and individuals located in a European or associated country:

- Scientific persons and research centers
- Universities
- Small, medium and large companies
- Students
- Public administrations, NGOs, etc..



SINGLE MARKET

Goals

Strengthening the governance of the EU's internal market, boosting competitiveness (particularly of SMEs), promoting human, animal and plant health and animal welfare, and establishing the framework for the financing of European statistics.

Content

Financing for:

- Improving the governance and functioning of the internal market. -
- Strengthen the competitiveness of EU enterprises, in particular micro-enterprises and SMEs.
- To promote the development of high quality European standards.
- Increasing consumer protection.
- Improve human, animal and plant health,

as well as animal welfare.

- Promote high quality, timely and reliable European statistics.

Type of projects

Data collection and analysis; studies and evaluations. Capacity building and facilitation of joint actions between member states, their competent authorities, the Commission and EU decentralized agencies. Funding mechanisms to enable individuals, consumers and business representatives to contribute to decision-making processes. Projects, tools and services to identify and address specific competitiveness and sustainability challenges. Exchange and dissemination of experiences and knowledge.

Implementation

SMP brings together 6 different programs from the previous period, such as COSME or Consumption, and is managed through direct and indirect management. It provides funding in the form of grants, awards and acquisitions.

Participants

Legal entities, in particular consumer organizations, statistical institutes, standardization organizations, authorities in the field of food and feed, animal health and welfare and plant health, SMEs and the Enterprise Europe Network, (EEN).

